CD16+ Monocytes in Coronary Heart Disease (CHD)
- Conditions
- Coronary Heart Disease
- Registration Number
- NCT01442948
- Lead Sponsor
- Martin-Luther-Universität Halle-Wittenberg
- Brief Summary
Monocytes may be separated into phenotypically and functionally distinct cell types by the presence or absence of the lipopolysaccharide receptor CD14 and the Fcγ-receptor CD16. The investigators hypothesize that the total numbers of CD16+ monocytes are significantly related to cardiovascular outcome in patients with angiographically proven coronary heart disease.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 1000
- angiographically proven coronary heart disease
- Age > 18 years
- life expectancy < 12 months
- inability to participate in the trial (to give written informed consent)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Absolute numbers of CD16+ monocytes stratified by tertiles related to the incidence of the combined endpoint 12 months Incidence of the combined endpoint (non-fatal myocardial infarction, cardiovascular death, stroke) during a follow-up of 12 months
- Secondary Outcome Measures
Name Time Method Absolute numbers of CD16+ monocytes stratified by tertiles related to the incidence of each part of the combined endpoint + total death 12 months * non-fatal myocardial infarction
* cardiovascular death
* stroke
* total deathSubgroup analysis for absolute numbers of CD16+ monocytes stratified by tertiles in relation to the combined endpoint 12 months Subgroups of patients:
Patients with stable Angina Patients with acute coronary syndrome
Trial Locations
- Locations (1)
University Clinic of the Martin Luther-University Halle-Wittenberg
🇩🇪Halle (Saale), Please Select, Germany